Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chrna4 in the preparation of drugs for the treatment of nonalcoholic steatohepatitis

A steatohepatitis, non-alcoholic technology, applied in the field of medicine, can solve the problems of insufficient clinical treatment methods for NASH, and achieve the effect of reducing liver lipid deposition

Active Publication Date: 2022-07-01
CHINA PHARM UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Technical problem to be solved: The present invention aims at the problem of insufficient clinical treatment methods for NASH at present, and provides CHRNA4 as a target in screening non-alcoholic steatohepatitis therapeutic drugs, preparing non-alcoholic steatohepatitis therapeutic drugs or preparing non-alcoholic steatohepatitis therapeutic drugs. Application of Hepatitis Diagnostic Drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chrna4 in the preparation of drugs for the treatment of nonalcoholic steatohepatitis
  • Application of chrna4 in the preparation of drugs for the treatment of nonalcoholic steatohepatitis
  • Application of chrna4 in the preparation of drugs for the treatment of nonalcoholic steatohepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] CHRNA4 is a potential therapeutic target for NASH

[0031] 1. Construction of high-fat feeding (HFD) and high-fat and high-glucose feeding (HFFD) models: 5-week-old male C57BL / 6J mice (purchased from Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd.) were incubated in a standard SPF environment (without Special pathogens, kept at a constant temperature of 25°C, with 12-hour interval lighting). At the beginning of modeling, the mice were divided into two groups, one group of mice was fed with high-fat diet (HFD) (high-fat diet was purchased from Research Diet, USA, product number D12492), and the other group of mice was fed with high-fat diet and fructose-containing food. The mice were fed with water (2.31 g fructose / 100 mL of drinking water) (HFFD) and fed ad libitum. After 21 weeks of feeding, the mice were dissected, and the materials were collected and tested.

[0032] Total RNA extraction and qPCR detection: Take an appropriate amount of the above-mentio...

Embodiment 2

[0075] Therapeutic effect of Lobeline Hydrochloride on NASH

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention utilizes high-fat and high-sugar diet-induced nonalcoholic steatohepatitis (NASH) mice to reveal that CHRNA4 can be used as a potential therapeutic target for NASH, and confirms the effect of its antagonist lobeline hydrochloride on NASH. Therapeutic effect provides a new way for the treatment of NASH.

Description

technical field [0001] The invention belongs to the technical field of medicine, in particular to the application of CHRNA4 in the preparation of a medicine for treating nonalcoholic steatohepatitis. Background technique [0002] The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing year by year in the world, and it has become one of the most common liver diseases in children and adults. Non-alcoholic steatohepatitis (NASH) is a further developed form of non-alcoholic steatohepatitis (NAFL), which is accompanied by liver cell damage and liver inflammation, which can further develop into liver fibrosis, liver cirrhosis, increased hepatocellular carcinoma and liver cancer. Risk of other liver-related deaths. NASH is emerging as the leading cause of liver transplantation, and there are no effective drugs. Therefore, it is imperative to explore potential therapeutic targets and develop effective drug treatments. [0003] Nicotinic acetylcholine receptors (no...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68G01N33/576A61K45/00A61P1/16
CPCG01N33/6893G01N33/576A61K45/00A61P1/16G01N2333/705
Inventor 王丽蕊高颖生潘楚玥刘俊
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com